RANIBIZUMAB Side Effects

7021524-7 | Cerebral Haemorrhage
on Sep 21, 2010 Male patient from UNITED STATES , 79 years of age, was diagnosed with medical diet, hypertension, gastrooesophageal reflux disease, hypercholesterolaemia and was treated with Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral haemorrhage. Ranibizumab dosage: Unk. During the same period patient was treated with ICAPS (Unk) (View Icaps Review and Icaps Label ), TENORMIN (Unk) (View Tenormin Review and Tenormin Label ), ZANTAC (Unk) (View Zantac Review and Zantac Label ), CRESTOR (Unk) (View Crestor Review and Crestor Label ), NORVASC (Unk) (View Norvasc Review and Norvasc Label ), OMEGA 3 MARINE TRIGLYCERIDES (Unk) (View Omega-3 Marine Triglycerides Review and Omega-3 Marine Triglycerides Label ), LYSINE (Unk) (View Lysine Review and Lysine Label ). Patient was hospitalized.

7019194-7 | Retinal Haemorrhage, Vitreous Haemorrhage
Patient was taking Ranibizumab (View Usage). Patient had the following side effects: retinal haemorrhage, vitreous haemorrhage on Sep 14, 2010 from SWITZERLAND Additional patient health information: Female patient , 64 years of age, . Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with LEVOFLOXACIN (Unk) (View Levofloxacin Review and Levofloxacin Label ), VISUDYNE (View Visudyne Review and Visudyne Label ). Patient was hospitalized.

7013850-2 | Polypoidal Choroidal Vasculopathy
Adverse event was reported on Sep 09, 2010 by a Female patient taking Ranibizumab (View Usage) (Dosage: ) . Location: SWITZERLAND , 76 years of age, After Ranibizumab was administered, patient had the following side effects: polypoidal choroidal vasculopathy.

7013849-6 | Polypoidal Choroidal Vasculopathy
on Sep 09, 2010 Male patient from SWITZERLAND , 79 years of age, was treated with Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: polypoidal choroidal vasculopathy. Ranibizumab dosage: .


7013806-X | Polypoidal Choroidal Vasculopathy, Visual Acuity Reduced
on Sep 09, 2010 Female patient from SWITZERLAND , 69 years of age, was treated with Ranibizumab (View Usage). Patient had the following side effects: polypoidal choroidal vasculopathy, visual acuity reduced. Ranibizumab dosage: Unk.

7013802-2 | Polypoidal Choroidal Vasculopathy
Patient was taking Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: polypoidal choroidal vasculopathy on Sep 09, 2010 from SWITZERLAND Additional patient health information: Male patient , 79 years of age, . Ranibizumab dosage: .

7013800-9 | Polypoidal Choroidal Vasculopathy
Adverse event was reported on Sep 09, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: Unk) . Location: SWITZERLAND , 75 years of age, Patient experienced the following unwanted or unexpected effects: polypoidal choroidal vasculopathy.

7013628-X | Eye Infection Toxoplasmal
on Sep 09, 2010 Female patient from SWITZERLAND , 53 years of age, was treated with Ranibizumab (View Usage). Patient had the following side effects: eye infection toxoplasmal. Ranibizumab dosage: 0.05 Ml, Unk.

7010612-7 | Subretinal Fibrosis
on Sep 08, 2010 Female patient from SWITZERLAND , 71 years of age, was treated with Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: subretinal fibrosis. Ranibizumab dosage: .

7008728-4 | Retinal Haemorrhage, Subretinal Fibrosis
Patient was taking Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: retinal haemorrhage, subretinal fibrosis on Sep 08, 2010 from SWITZERLAND Additional patient health information: Female patient , 71 years of age, . Ranibizumab dosage: .

7008456-5 | Subretinal Fibrosis
Adverse event was reported on Sep 08, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: ) . Location: SWITZERLAND , 75 years of age, Patient had the following side effects: subretinal fibrosis.

6993832-7 | Retinal Pigment Epithelial Tear
on Sep 03, 2010 Male patient from SWITZERLAND , 76 years of age, was treated with Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: retinal pigment epithelial tear. Ranibizumab dosage: Unk.

6993562-1 | Retinal Pigment Epithelial Tear
on Sep 03, 2010 Male patient from SWITZERLAND , 72 years of age, was treated with Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: retinal pigment epithelial tear. Ranibizumab dosage: Unk.

6992630-8 | Retinal Scar
Patient was taking Ranibizumab (View Usage). Patient had the following side effects: retinal scar on Sep 02, 2010 from SWITZERLAND Additional patient health information: Male patient , 82 years of age, . Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with MOXIFLOXACIN HYDROCHLORIDE (Unk) (View Moxifloxacin Hydrochloride Review and Moxifloxacin Hydrochloride Label ).

6981016-8 | Cerebral Infarction
Adverse event was reported on Aug 31, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: 0.05 Ml, Unk) . Location: SWITZERLAND , 70 years of age, After Ranibizumab was administered, patient had the following side effects: cerebral infarction. Patient was hospitalized.

6969484-9 | Cellulitis, Osteitis
on Aug 23, 2010 Male patient from SWITZERLAND , weighting 165.3 lb, was diagnosed with diabetic retinal oedema and was treated with Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cellulitis (What is cellulitis?), osteitis. Ranibizumab dosage: Unk. During the same period patient was treated with DOXIUM (View Doxium Review and Doxium Label ), DIAPREL (View Diaprel Review and Diaprel Label ), PRENESSA (View Prenessa Review and Prenessa Label ), INDAPAMIDE (View Indapamide Review and Indapamide Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), CARDURA (View Cardura Review and Cardura Label ), SYNCUMAR (View Syncumar Review and Syncumar Label ). Patient was hospitalized and became disabled.

6956699-9 | Ischaemic Cardiomyopathy
on Aug 18, 2010 Male patient from UNITED STATES , weighting 205.0 lb, was diagnosed with diabetic retinal oedema, blood pressure (What is blood pressure?), fluid retention, depression (What is depression?), diabetes mellitus and was treated with Ranibizumab (View Usage). Patient had the following side effects: ischaemic cardiomyopathy. Ranibizumab dosage: Unk. During the same period patient was treated with DIPYRIDAMOLE (Unk) (View Dipyridamole Review and Dipyridamole Label ), ENALAPRIL MALEATE (Unk) (View Enalapril Maleate Review and Enalapril Maleate Label ), FUROSEMIDE (80 Mg, Unk) (View Furosemide Review and Furosemide Label ), AMITRIPTYLINE HCL (Unk) (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ), AMILORIDE HCL AND HYDROCHLOROTHIAZIDE (Unk) (View Amiloride Hcl And Hydrochlorothiazide Review and Amiloride Hcl And Hydrochlorothiazide Label ), NOVOLIN N (Unk) (View Novolin N Review and Novolin N Label ), GLIPIZIDE (Unk) (View Glipizide Review and Glipizide Label ).

6943676-7 | Cerebral Infarction
Patient was taking Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: cerebral infarction on Aug 18, 2010 from UNITED STATES Additional patient health information: Female patient , 86 years of age, was diagnosed with choroidal neovascularisation, osteoporosis (What is osteoporosis?), anxiety (What is anxiety?), hypertension, oesophagitis, hyperlipidaemia, gastritis and. Ranibizumab dosage: Unk. During the same period patient was treated with ALENDRONATE SODIUM (Unk) (View Alendronate Sodium Review and Alendronate Sodium Label ), PAROXETINE HCL (Unk) (View Paroxetine Hcl Review and Paroxetine Hcl Label ), CALTRATE (Unk) (View Caltrate Review and Caltrate Label ), ATENOLOL (Unk) (View Atenolol Review and Atenolol Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

6941641-7 | Cardiac Operation, Mitral Valve Incompetence
Adverse event was reported on Aug 13, 2010 by a Female patient taking Ranibizumab (View Usage) (Dosage: Unk) . Location: SWITZERLAND , 82 years of age, Patient experienced the following unwanted or unexpected effects: cardiac operation, mitral valve incompetence. During the same period patient was treated with MACUGEN (View Macugen Review and Macugen Label ).

6934671-2 | Cataract Operation, Intraocular Lens Implant
on Aug 13, 2010 Female patient from UNITED STATES , 69 years of age, was treated with Ranibizumab (View Usage). Patient had the following side effects: cataract operation, intraocular lens implant. Ranibizumab dosage: Unk. During the same period patient was treated with EPI RAD 90 (Unk) (View Epi-rad 90 Review and Epi-rad 90 Label ).

6934644-X | Chest Pain
on Aug 13, 2010 Female patient from UNITED STATES , 62 years of age, was treated with Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: chest pain (What is chest pain?). Ranibizumab dosage: Unk. During the same period patient was treated with EPI RAD 90 (Unk) (View Epi-rad 90 Review and Epi-rad 90 Label ). Patient was hospitalized.

6933000-8 | Cataract, Herpes Simplex Ophthalmic
Patient was taking Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cataract (What is cataract?), herpes simplex ophthalmic on Aug 12, 2010 from UNITED STATES Additional patient health information: Male patient , 75 years of age, was diagnosed with vitamin supplementation, arthritis (What is arthritis?), hypersensitivity, hypertension, coronary artery disease (What is coronary artery disease?), depression (What is depression?) and. Ranibizumab dosage: Unk. During the same period patient was treated with EPI RAD 90 (Unk) (View Epi-rad 90 Review and Epi-rad 90 Label ), PRESERVISION AREDS (Unk) (View Preservision Areds Review and Preservision Areds Label ), OSTEO BI FLEX PRODUCT NOS (Unk) (View Osteo Bi-flex Product Nos Review and Osteo Bi-flex Product Nos Label ), CLARITIN (Unk) (View Claritin Review and Claritin Label ), BISOPROLOL (Unk) (View Bisoprolol Review and Bisoprolol Label ), ASPIRIN (Unk) (View Aspirin Review and Aspirin Label ), LEXAPRO (Unk) (View Lexapro Review and Lexapro Label ).

6923915-9 |
Adverse event was reported on Aug 09, 2010 by a Female patient taking Ranibizumab (View Usage) (Dosage: Unk) was diagnosed with retinal vein occlusion, prophylaxis, asthma (What is asthma?), depression (What is depression?), hypercholesterolaemia, arthritis (What is arthritis?), hypertension and. Location: UNITED STATES , weighting 154.3 lb, . During the same period patient was treated with ASPIRIN (Unk) (View Aspirin Review and Aspirin Label ), ADVAIR DISKUS 100/50 (Unk) (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ), ALBUTEROL (Unk) (View Albuterol Review and Albuterol Label ), FLONASE (Unk) (View Flonase Review and Flonase Label ), CELEXA (Unk) (View Celexa Review and Celexa Label ), LIPITOR (Unk) (View Lipitor Review and Lipitor Label ), LORTAB (Unk) (View Lortab Review and Lortab Label ), LOTREL (Unk) (View Lotrel Review and Lotrel Label ).

6922135-1 | Angina Unstable, Cerebellar Infarction
on Jul 30, 2010 Male patient from SWITZERLAND , 72 years of age, was treated with Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: angina unstable, cerebellar infarction. Ranibizumab dosage: . During the same period patient was treated with VISUDYNE (Unk) (View Visudyne Review and Visudyne Label ), GATIFLOXACIN (Unk) (View Gatifloxacin Review and Gatifloxacin Label ). Patient was hospitalized.

6921787-X |
on Aug 10, 2010 Male patient from UNITED STATES , weighting 205.0 lb, was diagnosed with diabetic retinal oedema and was treated with Ranibizumab (View Usage). . Ranibizumab dosage: Unk.

6911633-2 | Macular Hole, Vitreous Detachment
Patient was taking Ranibizumab (View Usage). Patient had the following side effects: macular hole, vitreous detachment on Jul 26, 2010 from SWITZERLAND Additional patient health information: Female patient , 67 years of age, was diagnosed with detachment of retinal pigment epithelium and. Ranibizumab dosage: .

6902418-1 |
Adverse event was reported on Jul 30, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: Unk) was diagnosed with diabetic retinal oedema and. Location: UNITED STATES , weighting 205.0 lb, .

6876996-5 | Pneumonia, Vitreous Haemorrhage
on Jul 14, 2010 Male patient from SWITZERLAND , 78 years of age, weighting 136.7 lb, was treated with Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia (What is pneumonia?), vitreous haemorrhage. Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with VISUDYNE (Unk) (View Visudyne Review and Visudyne Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), ADALAT (View Adalat Review and Adalat Label ), NIFLAN (Unk) (View Niflan Review and Niflan Label ).

6872820-5 |
on Jul 20, 2010 Female patient from UNITED STATES , weighting 154.3 lb, was diagnosed with retinal vein occlusion and was treated with Ranibizumab (View Usage). . Ranibizumab dosage: Unk.

6857613-7 | Detachment Of Retinal Pigment Epithelium, Endophthalmitis
Patient was taking Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: detachment of retinal pigment epithelium, endophthalmitis on Jul 06, 2010 from JAPAN Additional patient health information: Male patient , 85 years of age, weighting 108.0 lb, was diagnosed with prophylaxis and. Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with ANTIBIOTICS (NOT SPECIFIED) (Unk) (View Antibiotics (not Specified) Review and Antibiotics (not Specified) Label ), VISUDYNE (Unk) (View Visudyne Review and Visudyne Label ), LEVOFLOXACIN (Unk) (View Levofloxacin Review and Levofloxacin Label ), AVASTIN (Unk) (View Avastin Review and Avastin Label ). Patient was hospitalized.

6844994-3 | Dizziness, Vertigo Positional
Adverse event was reported on Jul 02, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: 0.05 /ml, Unk) . Location: JAPAN , weighting 156.5 lb, Patient experienced the following unwanted or unexpected effects: dizziness (What is dizziness?), vertigo positional. During the same period patient was treated with VISUDYNE (Unk) (View Visudyne Review and Visudyne Label ), GATIFLOXACIN (Unk) (View Gatifloxacin Review and Gatifloxacin Label ), ADONA (Unk) (View Adona Review and Adona Label ), KALLIDINOGENASE (Unk) (View Kallidinogenase Review and Kallidinogenase Label ).

6844595-7 | Hospitalisation
on Jul 01, 2010 Male patient from UNITED STATES , 66 years of age, was diagnosed with diabetic retinal oedema, hypertension, diabetes mellitus, anxiety (What is anxiety?), neuropathy peripheral, hypercholesterolaemia and was treated with Ranibizumab (View Usage). Patient had the following side effects: hospitalisation. Ranibizumab dosage: 0.5 Mg, Prn. During the same period patient was treated with ALTACE (Unk) (View Altace Review and Altace Label ), AMARYL (Unk) (View Amaryl Review and Amaryl Label ), METFORMIN HCL (Unk) (View Metformin Hcl Review and Metformin Hcl Label ), CYMBALTA (Unk) (View Cymbalta Review and Cymbalta Label ), LIPITOR (Unk) (View Lipitor Review and Lipitor Label ), SYNTHROID (Unk) (View Synthroid Review and Synthroid Label ). Patient was hospitalized.

6844592-1 | Cytomegalovirus Chorioretinitis, Eye Disorder, Eye Inflammation, Necrosis, Retinal Disorder, Vasculitis, Vitrectomy
on Jul 01, 2010 Male patient from SWITZERLAND , 83 years of age, was treated with Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: cytomegalovirus chorioretinitis, eye disorder, eye inflammation, necrosis, retinal disorder (What is retinal disorder?), vasculitis (What is vasculitis?), vitrectomy. Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with AVASTIN (Unk) (View Avastin Review and Avastin Label ), TRIAMCINOLONE ACETONIDE (Unk) (View Triamcinolone Acetonide Review and Triamcinolone Acetonide Label ). Patient was hospitalized.

6844591-X | Cytomegalovirus Chorioretinitis, Eye Disorder, Eye Inflammation, Necrosis, Retinal Disorder, Vasculitis, Vitrectomy
Patient was taking Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cytomegalovirus chorioretinitis, eye disorder, eye inflammation, necrosis, retinal disorder (What is retinal disorder?), vasculitis (What is vasculitis?), vitrectomy on Jul 01, 2010 from SWITZERLAND Additional patient health information: Male patient , 83 years of age, . Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with AVASTIN (Unk) (View Avastin Review and Avastin Label ), TRIAMCINOLONE ACETONIDE (Unk) (View Triamcinolone Acetonide Review and Triamcinolone Acetonide Label ). Patient was hospitalized.

6840725-1 | Retinal Scar
Adverse event was reported on Jul 01, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: 0.05 Ml, Unk) . Location: SWITZERLAND , 82 years of age, Patient had the following side effects: retinal scar. During the same period patient was treated with MOXIFLOXACIN HYDROCHLORIDE (Unk) (View Moxifloxacin Hydrochloride Review and Moxifloxacin Hydrochloride Label ).

6837537-1 | Arrhythmia, Cardiac Failure, Pneumonia
on Jul 01, 2010 Male patient from UNITED STATES , weighting 185.2 lb, was diagnosed with macular oedema, gastrooesophageal reflux disease, diabetes mellitus, hypertension, gout (What is gout?), left ventricular dysfunction, hypokalaemia, hyperlipidaemia and was treated with Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: arrhythmia (What is arrhythmia?), cardiac failure, pneumonia (What is pneumonia?). Ranibizumab dosage: Unk. During the same period patient was treated with NEXIUM (Unk) (View Nexium Review and Nexium Label ), GLYBURIDE (Unk) (View Glyburide Review and Glyburide Label ), NORVASC (Unk) (View Norvasc Review and Norvasc Label ), ALLOPURINOL (Unk) (View Allopurinol Review and Allopurinol Label ), COREG (Unk) (View Coreg Review and Coreg Label ), K DUR (Unk) (View K-dur Review and K-dur Label ), LABETALOL HCL (Unk) (View Labetalol Hcl Review and Labetalol Hcl Label ), LIPITOR (Unk) (View Lipitor Review and Lipitor Label ). Patient was hospitalized.

6827305-9 | Cataract Subcapsular, Eye Inflammation, Retinal Disorder, Vitreous Injury
on Jun 25, 2010 Female patient from SWITZERLAND , weighting 116.8 lb, was treated with Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cataract subcapsular, eye inflammation, retinal disorder (What is retinal disorder?), vitreous injury. Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with LEVOFLOXACIN (Unk) (View Levofloxacin Review and Levofloxacin Label ).

6827089-4 | Visual Acuity Reduced, Vitreous Haemorrhage
Patient was taking Ranibizumab (View Usage). Patient had the following side effects: visual acuity reduced, vitreous haemorrhage on Jun 24, 2010 from SWITZERLAND Additional patient health information: Male patient , 74 years of age, . Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with GATIFLOXACIN (Unk) (View Gatifloxacin Review and Gatifloxacin Label ).

6818550-7 | Anaemia, Blood Pressure Decreased, Bradycardia, Dyspnoea, Oxygen Saturation Decreased, Renal Impairment
Adverse event was reported on Jun 15, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: Unk) was diagnosed with diabetic retinal oedema and. Location: SWITZERLAND , weighting 198.4 lb, After Ranibizumab was administered, patient had the following side effects: anaemia, blood pressure decreased, bradycardia, dyspnoea, oxygen saturation decreased, renal impairment. During the same period patient was treated with ACTOS (View Actos Review and Actos Label ), AMARYL (View Amaryl Review and Amaryl Label ), LOSARTAN POTASSIUM (View Losartan Potassium Review and Losartan Potassium Label ), ATELEC (View Atelec Review and Atelec Label ), DIGOSIN (View Digosin Review and Digosin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ETHYL ICOSAPENTATE (View Ethyl Icosapentate Review and Ethyl Icosapentate Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ). Patient was hospitalized.

6803409-1 | Meningitis Bacterial
on Jun 14, 2010 Male patient from SWITZERLAND , 74 years of age, was treated with Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: meningitis bacterial. Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with LOXONIN (Unk) (View Loxonin Review and Loxonin Label ), MUCOSIL 20 (Unk) (View Mucosil-20 Review and Mucosil-20 Label ), DEXAMETHASONE (Unk) (View Dexamethasone Review and Dexamethasone Label ), CEFTRIAXONE SODIUM (Unk) (View Ceftriaxone Sodium Review and Ceftriaxone Sodium Label ), VICCILLIN (Unk) (View Viccillin Review and Viccillin Label ), VANCOMYCIN (Unk) (View Vancomycin Review and Vancomycin Label ), OMEPRAL (Unk) (View Omepral Review and Omepral Label ).

6801545-7 | Cataract Subcapsular
on Jun 16, 2010 Female patient from SWITZERLAND , weighting 116.8 lb, was treated with Ranibizumab (View Usage). Patient had the following side effects: cataract subcapsular. Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with LEVOFLOXACIN (Unk) (View Levofloxacin Review and Levofloxacin Label ).

6786976-6 | Macular Hole, Visual Acuity Reduced
Patient was taking Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: macular hole, visual acuity reduced on Jun 10, 2010 from SWITZERLAND Additional patient health information: Male patient , 73 years of age, . Ranibizumab dosage: .

6775403-0 | Renal Failure Chronic
Adverse event was reported on Jun 09, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: Unk) was diagnosed with macular oedema, prophylaxis, fluid retention, neuropathy peripheral, blood cholesterol increased, diabetes mellitus and. Location: UNITED STATES , weighting 205.0 lb, Patient experienced the following unwanted or unexpected effects: renal failure chronic. During the same period patient was treated with LASER TREATMENT (Unk) (View Laser Treatment Review and Laser Treatment Label ), DIPYRIDAMOL (Unk) (View Dipyridamol Review and Dipyridamol Label ), FUROSEMIDE (80 Mg, Unk) (View Furosemide Review and Furosemide Label ), GABAPENTIN (Unk) (View Gabapentin Review and Gabapentin Label ), TRICOR (Unk) (View Tricor Review and Tricor Label ), NOVOLIN (Unk) (View Novolin Review and Novolin Label ), NOVOLIN R (Unk) (View Novolin R Review and Novolin R Label ). Patient was hospitalized.

6773213-1 |
on Jun 04, 2010 Male patient from SWITZERLAND , 74 years of age, was treated with Ranibizumab (View Usage). . Ranibizumab dosage: 0.05 Ml, Unk.

6770772-X | Retinal Pigment Epithelial Tear
on May 26, 2010 Female patient from SWITZERLAND , 76 years of age, was treated with Ranibizumab (View Usage). After Ranibizumab was administered, patient had the following side effects: retinal pigment epithelial tear. Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with VISUDYNE (Unk) (View Visudyne Review and Visudyne Label ), GATIFLOXACIN (Unk) (View Gatifloxacin Review and Gatifloxacin Label ).

6768726-2 | Visual Acuity Reduced
Patient was taking Ranibizumab (View Usage). Patient experienced the following unwanted or unexpected effects: visual acuity reduced on Jun 01, 2010 from SWITZERLAND Additional patient health information: Male patient , 77 years of age, . Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with LEVOFLOXACIN (Unk) (View Levofloxacin Review and Levofloxacin Label ), VISUDYNE (Unk) (View Visudyne Review and Visudyne Label ), KALLIDINOGENASE (Unk) (View Kallidinogenase Review and Kallidinogenase Label ).

6763190-1 | Macular Hole, Visual Acuity Reduced
Adverse event was reported on May 28, 2010 by a Male patient taking Ranibizumab (View Usage) (Dosage: ) was diagnosed with choroidal neovascularisation and. Location: SWITZERLAND , 73 years of age, Patient had the following side effects: macular hole, visual acuity reduced.

6761350-7 |
on Jun 03, 2010 Male patient from UNITED STATES , weighting 185.2 lb, was diagnosed with macular oedema, gastrooesophageal reflux disease, diabetes mellitus, hypertension, gout (What is gout?), left ventricular dysfunction, hypokalaemia, hyperlipidaemia and was treated with Ranibizumab (View Usage). . Ranibizumab dosage: Unk. During the same period patient was treated with NEXIUM (Unk) (View Nexium Review and Nexium Label ), GLYBURIDE (Unk) (View Glyburide Review and Glyburide Label ), NORVASC (Unk) (View Norvasc Review and Norvasc Label ), ALLOPURINOL (Unk) (View Allopurinol Review and Allopurinol Label ), COREG (Unk) (View Coreg Review and Coreg Label ), K DUR (Unk) (View K-dur Review and K-dur Label ), LABETALOL HCL (Unk) (View Labetalol Hcl Review and Labetalol Hcl Label ), LIPITOR (Unk) (View Lipitor Review and Lipitor Label ).

6761292-7 |
on May 28, 2010 Male patient from SWITZERLAND , 74 years of age, was treated with Ranibizumab (View Usage). . Ranibizumab dosage: 0.05 Ml, Unk.

6760744-3 | Retinal Pigment Epithelial Tear
Patient was taking Ranibizumab (View Usage). Patient had the following side effects: retinal pigment epithelial tear on May 26, 2010 from SWITZERLAND Additional patient health information: Female patient , 76 years of age, . Ranibizumab dosage: 0.05 Ml, Unk. During the same period patient was treated with VISUDYNE (Unk) (View Visudyne Review and Visudyne Label ), GATIFLOXACIN (Unk) (View Gatifloxacin Review and Gatifloxacin Label ).